Issue Date: March 19, 2012
Tough Times For Neuroscience R&D
When AstraZeneca revealed plans last month to step away from internal neuroscience R&D, the European College of Neuropsychopharmacology released a statement expressing alarm that yet another big pharma firm was pulling out of the field. “There is a growing sense that neuroscience in Europe is now facing a severe crisis,” the group said.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society